Clinical trial register · Germany

Clinical Trials in Hanover, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5060 matching records held by the registry are in this view. Synced 14 Oct 2026, 03:18 UTC

5060

Studies in scope

all four open statuses

2879

Recruiting now

open to new participants

987

Lead sponsors

across recruiting studies

Top sites

Berlin 1589 Hamburg 891 Essen 764 Dresden 713 Heidelberg 627

Trials with a site in Hanover

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen

2027-11-23

Not yet open

DEXA Bone Density Analysis of the CoreHip® Prosthesis System

NCT06632301Primary Osteoarthritis, Cartilage Degeneration, Osteoarthritis, Hip, Inflammatory Arthritis

Aesculap AG

Not applicable

Hanover

2026-12

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne

2026-11-30

Not yet open

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732Haemophilia A

Novo Nordisk A/S

Phase 3

Berlin, Bonn, Hanover, Leipzig, Regensburg

2026-10-09

Recruiting

Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)

NCT05880524Ischemic Stroke, Inflammatory Response

DrugDornase Alfa

Ludwig-Maximilians - University of Munich

Phase 2

Munich, Berlin, Hamburg, Hanover

2026-10-01

Not yet open

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

NCT07762027Chronic Hepatitis D Infection

Assembly Biosciences

Phase 2

Hamburg, Hanover

2026-10

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Berlin, Bonn, Essen, Hanover, Heidelberg, Immenhausen, München, Stuttgart

2026-09-17

Recruiting

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

NCT07851025Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

950

Berlin, Bonn, Hanover, Wiesbaden

2026-09-16

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

NCT07619118Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

200

Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hanover, Kaiserslautern, Leipzig, Munich

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg

2026-09-08

Recruiting

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

NCT07625215Atrial Fibrillation

Bayer

Phase 2

360

Hanover, Bad Oeynhausen, Altenburg

2026-09-01

Recruiting

Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

NCT07654855Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy

AstraZeneca

Observational

320

Hanover

2026-09-01

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463Obesity, Overweight, Chronic Weight Management

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

3,003

Berlin, Essen, Hanover, Leipzig

2026-08-31

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

1,560

Berlin, Essen, Hanover

2026-08-28

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Berlin, Bochum, Hanover, Hohenmölsen, Karlsruhe, Leipzig, Obertshausen, Offenbach

2026-08-26

Recruiting

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

NCT07739914Liver Allograft, Liver Diseases, Liver Transplantation

DrugsCyclosporine·Tacrolimus·Everolimus

Hannover Medical School

Phase 3

150

Heidelberg, Tübingen, Regensburg, Würzburg, Hamburg, Hanover, Rostock, Aachen

2026-08-19

Recruiting

Induced Sputum Collection in COPD Patients With and Without a Vibroacoustic Device

NCT07751705COPD (Chronic Obstructive Pulmonary Disease)

Fraunhofer-Institute of Toxicology and Experimental Medicine

Not applicable

Hanover

2026-08-18

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

600

Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig

2026-08-12

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

Aachen, Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Hanover

2026-08-05

Not yet open

D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab

NCT07684066Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

Universitätsklinikum Hamburg-Eppendorf

Observational

116

Bielefeld, Bremerhaven, Buxtehude, Erlangen, Göttingen, Hamburg, Hanover, Kiel

2026-08-01

Recruiting

Auditory Intranerve Stimulation Perceptual Study

NCT07789665Deafness, Perception

Hannover Medical School

Not applicable

Hanover

2026-08

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster

2026-07-27

Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034Fibrosing Interstitial Lung Disease

DrugNerandomilast

Boehringer Ingelheim

Phase 3

Berlin, Hamburg, Hanover

2026-07-21

Recruiting

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura

DrugZugo-cel

CRISPR Therapeutics AG

Phase 1/2

Cologne, Hannover, Hanover, Mainz

2026-07-17

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne

2026-07-16

Recruiting

Evaluation of a Mobile Menopause Application

NCT07663305N95.1 Menopausal and Female Climacteric States

Endo Health GmbH

Not applicable

426

Hanover

2026-07-06

Not yet open

Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer

NCT07627022Lung Cancer

University Hospital Schleswig-Holstein

Not applicable

Hanover, Kiel, Lübeck

2026-07-01

Recruiting

I-scoop vs. C-Mac D-Blade Videolaryngoscope for Airway Management Under Spontaneous Breathing and Analgosedation

NCT07624162Airway Management

Hannover Medical School

Not applicable

200

Hanover

2026-06-18

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Bonn, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg

2026-06-11

Not yet open

SCI-110 in the Treatment of Tourette Syndrome

NCT05126888Tourette Syndrome

Neurothera Labs Inc.

Phase 2

164

Hanover

2026-06

Recruiting

MacuTherm Performance Study in Patients With iAMD

NCT07607496Intermediate AMD

OD-OS MacuTherm GmbH

Not applicable

240

Detmold, Hanover, Lübeck, Mannheim, Münster, Potsdam, Schleswig, Trier

2026-05-29

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856Colitis, Ulcerative

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

644

Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Jena, Karlshorst

2026-05-23

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843Crohn Disease

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

460

Berlin, Dresden, Hanover, Kiel, Leipzig, Mannheim, Rostock

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Essen, Dessau, Hamburg, Hanover, Heidelberg, Koblenz, Langen, München

2026-05-21

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Regensburg

2026-05-20

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Berlin, Dresden, Hanover, Heidelberg, Leipzig, Magdeburg, Mainz, Tübingen

2026-05-14

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen

2026-05-11

Recruiting

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig

2026-05-05

Recruiting

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig

2026-05-05

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)

Liquidia Technologies, Inc.

Phase 3

344

Cologne, Giessen, Greifswald, Hamburg, Hanover, Munich

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Hanover

2026-04-23

Recruiting

Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants

NCT06626490Revision Total Hip Arthroplasty, Periprosthetic Fracture of Hip

Aesculap AG

Observational

120

Hanover

2026-04-07

Not yet open

Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting

NCT07549607Primary Bilary Cirrhosis (PBC)

University of Leipzig

Observational

100

Berlin, Frankfurt, Hamburg, Hanover, Heidelberg, Herne, Homburg, Jena

2026-04-01

Not yet open

DuoCor 2 DOMINATE Study

NCT07233876Advanced Heart Failure

Shenzhen Core Medical Technology CO.,LTD.

Not applicable

Hanover

2026-04-01

Recruiting

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906Immunoglobulin A Nephropathy (IgAN)

DrugZigakibart

Novartis Pharmaceuticals

Phase 2

Munich, Hanover, Mainz

2026-03-26

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Berlin, Cologne, Hamburg, Hanover, Mainz, München

2026-03-23

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

DrugsVisugromab RDE·Visugromab·Opdivo·Lenvatinib

CatalYm GmbH

Phase 2

104

Hanover, Mainz, Frankfurt

2026-03-19

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Münster, Tübingen

2026-03-17

Recruiting

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

NCT07457580Type 1 Diabetes

DrugTeplizumab

Sanofi

Observational

Frankfurt, Hanover

2026-03-16

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen

2026-03-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Lübeck

2026-03-05

Recruiting

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814Acute Myeloid Leukemia

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

875

Aachen, Bochum, Bonn, Braunschweig, Greifswald, Halle, Hamburg, Hanover

2026-03-01

Recruiting

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

NCT07454837Chronic Hepatitis D

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 2/3

120

Düsseldorf, Frankfurt, Hamburg, Hanover, Rostock

2026-02-26

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg

2026-02-16

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

800

Bamberg, Berlin, Essen, Hanover, Karlsruhe, Marburg, Oldenburg, Schwerin

2026-02-10

Recruiting

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

Essen, Hanover, Immenhausen, Solingen

2026-02-10

Recruiting

T-cell Therapy in Patients With PML

NCT06990087Progressive Multifocal Leucoencephalopathy (PML)

Hannover Medical School

Phase 2

München, Marburg, Hanover, Düsseldorf, Essen, Kiel

2026-02-06

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Hanover, Hof, Karlsburg, Ludwigshafen am Rhein, München, Oldenburg, Sankt Augustin, Ulm

2026-02-05

Recruiting

Exercise Training in Patients With Myeloproliferative Neoplasms

NCT07384039Myeloproliferative Neoplasms (MPN)

Hannover Medical School

Not applicable

Hanover

2026-02-04

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Augsburg, Dresden, Hanover, München

2026-01-12

Active, closed

Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis

NCT07378202Autoimmune Hepatitis

Hannover Medical School

Observational

5,000

Dresden, Hanover

2026-01-05

Recruiting

Dyadic, App-supported Collaborative Care Intervention Trial for Family Caregivers of People Living With Dementia

NCT07251088Dementia, Nurse Care Coordination, Informal Caregiver

German Center for Neurodegenerative Diseases (DZNE)

Not applicable

554

Karlsruhe, Konstanz, Reutlingen, Darmstadt, Hanover, Göttingen, Greifswald, Rostock

2026-01-01

Recruiting

OutreAch MediCal Care for HousEbound Patients With Post-COVID-19 Syndrome or ME/CFS of Any Cause (ACCESS)

NCT07352254ME/CFS

Hannover Medical School

Not applicable

100

Hanover

2026-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt

2025-12-31

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686Obesity, Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg

2025-12-19

Recruiting

PARO-agitation-study

NCT07568093Agitation, POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DECLINE, Anxiety After Surgery, Postoperative Pain

Hannover Medical School

Not applicable

300

Hanover

2025-12-15

Recruiting

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery

Ascendis Pharma A/S

Phase 3

186

Cologne, Düsseldorf, Hanover, Tübingen

2025-12-12

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Bonn, Essen, Frankfurt, Giessen, Hanover, Leipzig, Regensburg, Rostock

2025-12-03

Recruiting

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

NCT07203768Polycythemia Vera, Thrombocythemia

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

678

Halle, Hanover, Minden

2025-12-01

Recruiting

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

NCT06847542Neovascular Age-related Macular Degeneration

DrugRanibizumab

Hoffmann-La Roche

Phase 3

250

Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg

2025-11-27

Recruiting

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291Amyotrophic Lateral Sclerosis (ALS)

DrugsCromolyn Sodium·Riluzole

PhenoNet, Inc.

Phase 2

105

Berlin, Hanover, Lübeck

2025-11-25

Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531Type 1 Diabetes

SAb Biotherapeutics, Inc.

Phase 2

159

Augsburg, Hanover, Oberschleißheim

2025-11-25

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

NCT07226765Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg

2025-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover

2025-11-24

Recruiting

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT07073950Chronic Obstructive Pulmonary Disease, Hyperinflation

AstraZeneca

Phase 4

Ahrensburg, Berlin, Frankfurt, Hanover

2025-11-24

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Essen, Hanover

2025-11-13

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Berlin, Darmstadt, Essen, Frankfurt, Halle, Hanover, Konstanz, München

2025-11-06

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein

2025-11-05

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Berlin, Bonn, Hanover

2025-10-23

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg

2025-10-15

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Tübingen, Hanover, Essen, Dresden, Hamburg, Heidelberg

2025-10-07

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig

2025-10-03

Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099Sjögren, Sjogren Disease, Sjogren's Syndrome

DrugCLN-978

Cullinan Therapeutics Inc.

Phase 1

Erlangen, Hanover

2025-10-01

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Aachen, Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel

2025-10-01

Recruiting

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease

AllRock Bio, Inc.

Phase 2

Hanover

2025-10-01

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Heidelberg, Nürtingen, Munich, Nuremberg, Regensburg, Hanover, Kiel, Jena

2025-09-30

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Berlin, Erlangen, Hanover, Minden, Ulm

2025-09-26

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Phase 2

240

Dresden, Hanover, Jena, Lübeck, Rostock, Ulm

2025-09-17

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach

2025-09-15

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen

2025-09-11

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg

2025-09-08

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Frankfurt, Rostock, Düsseldorf, Hanover

2025-08-27

Recruiting

Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis

NCT07169526Self-Efficacy, Health Literacy, Liver Cirrhosis, ALD - Alcoholic Liver Disease

Hannover Medical School

Observational

200

Hanover

2025-08-11

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich

2025-08-06

Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458Refractory Metastatic Colorectal Cancer

DrugsMelphalan·Trifluridine/Tipiracil·Bevacizumab

Delcath Systems Inc.

Phase 2

Hanover, Leipzig

2025-08-05

Active, closed

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

NCT07142811Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 2

100

Hanover

2025-08-05

Recruiting

HOPE Against Cancer Recurrence in HCC

NCT06717919Liver Transplantation, HCC, Oncological Outcomes

Philipp Dutkowski

Phase 4

220

Essen, Hamburg-Eppendorf, Hanover, Heidelberg, Mainz, München

2025-08-01

Recruiting

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

NCT07096193Chronic Hepatitis Delta

Gilead Sciences

Phase 1/2

200

Hanover

2025-07-31

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

Berlin, Essen, Frankfurt am Main, Hanover

2025-07-30

Active, closed

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365Type 1 Interferonopathies

Boehringer Ingelheim

Phase 1

Dresden, Hanover, Tübingen

2025-07-29

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Not applicable

400

Giessen, Hanover, Heidelberg

2025-07-28

Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280Hereditary Angioedemas

CSL Behring

Observational

200

Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin

2025-07-21

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg

2025-07-02

Not yet open

Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer

NCT06653751Prostate Cancer Patients Treated by Radiotherapy

University Hospital Schleswig-Holstein

Not applicable

Hanover, Schwerin, Flensburg, Lübeck

2025-07-01

Recruiting

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel

2025-06-30

Active, closed

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

NCT06979531Primary Sjögren's Syndrome

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

180

Bad Doberan, Hamburg, Hanover, Heidelberg, Munich

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Ahrensburg, Bendorf, Berlin, Darmstadt, Halle, Hanover, Landsberg, Leipzig

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel

2025-06-27

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam

2025-06-26

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

573

Bad Bentheim, Göttingen, Hanover, Kiel, Langenau, Merzig

2025-06-12

Recruiting

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT06513286Chronic Hepatitis B

Michael Hoelscher

Phase 1/2

Frankfurt, Hamburg, Hanover, Leipzig, Munich

2025-06-12

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Heidelberg, Munich, Hanover, Cologne, Berlin

2025-06-09

Recruiting

Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time

NCT06874296Liver Transplantation, Liver Diseases, Surgery

Charite University, Berlin, Germany

Not applicable

186

Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg

2025-06-02

Active, closed

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Blueprint Medicines Corporation

Phase 2

105

Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen

2025-05-28

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg

2025-05-22

Recruiting

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

DrugsTAK-881·Phesgo

Takeda

Phase 3

Mannheim, Ulm, Marburg, Hanover, Berlin

2025-05-06

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne

2025-04-24

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Hanover, Berlin, Frankfurt

2025-04-17

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen

2025-04-09

Recruiting

Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia

NCT06740747Schizophrenia Patients

Hannover Medical School

Not applicable

Hanover

2025-04-08

Active, closed

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166COPD, Smoking, Tobacco Use

Philip Morris Products S.A.

Not applicable

290

Berlin, Delitzsch, Hanover, Karlsruhe, Leipzig, Neu-Isenburg, Offenbach, Reinfeld

2025-04-02

Recruiting

The Dragon PLC Trial (DRAGON-PLC)

NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

Maastricht University

Not applicable

358

Cologne, Dresden, Hanover

2025-04-01

Recruiting

Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only

NCT06867705Cancer

Resilience

Phase 3

1,458

Augsburg, Bad Saarow, Bochum, Hamburg, Hanover, Hösbach, Kiel, Lübeck

2025-04-01

Active, closed

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

NCT06867094Colitis Ulcerative

DrugBalinatunfib

Sanofi

Phase 2

204

Berlin, Duisburg, Frankfurt, Hanover, Tübingen, Ulm

2025-03-28

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Berlin, Frankfurt, Hanover

2025-03-20

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Bendorf, Berlin, Haltern am See, Hanover, Immenhausen, Lübeck, Marburg, Rosenheim

2025-03-18

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm

2025-03-17

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Frankfurt, Hanover, Münster, Ulm, Würzburg

2025-03-14

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg

2025-03-12

Active, closed

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

NCT06903338Viral Hepatitis

DrugsTobevibart·Elebsiran

Vir Biotechnology, Inc.

Phase 3

124

Frankfurt, Hanover, Heidelberg

2025-03-12

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis

DrugZugo-cel

CRISPR Therapeutics

Phase 1

Augsburg, Cologne, Hanover, Mainz

2025-03-10

Recruiting

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT06764706Ulcerative Colitis

AbbVie

Observational

200

Heidelberg, Potsdam, Tostedt, Hanover, Schwerin, Ahaus, Bochum, Cologne

2025-02-27

Recruiting

Validation of the TheraSure CNI-Monitor Under Immuno-checkpoint-therapy (Hereinafter: "Immunotherapy") in NSCLC in Palliative Therapy

NCT05426668NSCLC

Karsten Gavenis

Observational

170

Göttingen, Hanover, Oldenburg

2025-02-24

Recruiting

A Multicenter, Multinational, Cohort Long-term Post-market Clinical Follow-up (PMCF) of the Safety and Efficacy of the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System When Used for Transhumeral Implantation in Amputee Patients

NCT06753110Amputation of Upper Limb

Integrum

Not applicable

Hanover, Tübingen

2025-02-19

Recruiting

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

NCT06752122Healthy Volunteers, Safety, Tolerability, Pharmacokinetics

RNATICS GmbH

Phase 1

Hanover

2025-02-18

Not yet open

A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy

NCT06784115Prostate Cancer Patients Treated by Radiotherapy

University Hospital Schleswig-Holstein

Not applicable

Hanover, Lübeck

2025-02-15

Recruiting

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

NCT06456983Schizophrenia, Treatment Resistant Schizophrenia

Central Institute of Mental Health, Mannheim

Not applicable

140

Aachen, Augsburg, Göppingen, Göttingen, Hanover, Heidelberg, Ingolstadt, Mainz

2025-02-14

Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098Thrombocytopenia, Neonatal Alloimmune

DrugsImmunoglobulins·Nipocalimab·IVIG·Prednisone

Janssen Research & Development, LLC

Phase 3

Giessen, Hanover, Jena, Tübingen

2025-02-10

Recruiting

LEOPARD Training and Validation Data Collection Study

NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Observational

4,500

Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen

2025-02-04

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Amberg, Planegg, Hohen Neuendorf, Templin, Frankfurt am Main, Wetzlar, Hanover, Kassel

2025-01-31

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Tübingen, Munich, Hamburg, Hanover

2025-01-15

Active, closed

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420Hereditary Angioedema

Intellia Therapeutics

Phase 3

Berlin, Frankfurt, Hanover

2025-01-15

Recruiting

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549Geographic Atrophy of the Macula

Galimedix Therapeutics Inc

Phase 2

110

Bonn, Freiburg im Breisgau, Hanover, Neubrandenburg, Tübingen, Ulm

2025-01-10

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Cologne, Frankfurt, Göttingen, Hanover, Hösbach, Koblenz

2025-01-03

Recruiting

Dermatitis During Adjuvant Irradiation for BREAst Cancer:

NCT06483477Breast Cancer Female

University Hospital Schleswig-Holstein

Not applicable

268

Hanover, Schwerin, Flensburg, Lübeck

2024-12-23

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Berlin, Dresden, Hanover

2024-12-19

Recruiting

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

AstraZeneca

Observational

300

Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz

2024-12-16

Active, closed

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin

Institut de Recherches Internationales Servier

Phase 1/2

Berlin, Düsseldorf, Frankfurt, Hanover, Ulm

2024-12-16

Recruiting

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension

Abbott Medical Devices

Not applicable

850

Leipzig, Hanover, Berlin

2024-12-13

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Bochum, Frankfurt am Main, Hamburg, Hanover, Heilbronn, Magdeburg, Riesa, Ulm

2024-12-13

Recruiting

Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

NCT06745557Burns

DrugsDenovoSkin·Ehsg-Kf

CUTISS AG

Phase 3

Berlin, Halle, Hanover, Murnau am Staffelsee

2024-12-13

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

Hanover, Jena

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Freiburg im Breisgau, Frankfurt am Main, Hanover

2024-12-09

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin

2024-12-09

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München

2024-12-04

Recruiting

Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

NCT06743035Polycythemia Vera

iOMEDICO AG

Observational

200

Hanover

2024-12-03

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Berlin, Frankfurt, Hanover

2024-12-01

By invitation

PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs

NCT06718322Focus of Study: Tailored Implementation

Hidde van der Ploeg

Not applicable

100

Berlin, Hanover, Heidelberg

2024-12-01

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf

2024-11-25

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

Amberg, Bielefeld, Dresden, Hamburg, Hanover, Heilbronn, Reutlingen

2024-11-22

Active, closed

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

NCT06460506Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

Berlin, Essen, Hanover

2024-11-21

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Alzenau in Unterfranken, Berlin, Braunschweig, Dresden, Essen, Hanover, Heidelberg, Kiel

2024-11-19

Active, closed

Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma

NCT06545175Hearing Loss

Hannover Medical School

Phase 1/2

Hanover

2024-11-18

Active, closed

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease

DrugTaladegib

Endeavor Biomedicines, Inc.

Phase 2

213

Giessen, Immenhausen, Hanover, Essen, Berlin, Leipzig

2024-11-15

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Berlin, Hanover, Münster

2024-11-11

Recruiting

Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06648096Fanconi Anemia, Head and Neck Squamous Cell Carcinoma

DrugAfatinib

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 1/2

Hanover

2024-11-08

Recruiting

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome

NCT06380686Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Larynx

AIO-Studien-gGmbH

Observational

120

Essen, Hanover

2024-11-07

Active, closed

Pneumonitis in Older Lung Cancer Patients After Radiotherapy

NCT06480734Lung Cancer

University Hospital Schleswig-Holstein

Not applicable

Hanover, Schwerin, Flensburg, Lübeck

2024-11-06

By invitation

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

NCT06472362Systemic Sclerosis

Royal Brompton & Harefield NHS Foundation Trust

Observational

1,000

Hanover

2024-11-01

Recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593Moderately to Severely Active Crohn Disease

DrugObefazimod

Abivax S.A.

Phase 2

212

Berlin, Brandenburg an der Havel, Erlangen, Frankfurt am Main, Hamburg, Hanover, Heidelberg, Kiel

2024-10-30

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster

2024-10-17

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Halle, Hanover, Minden

2024-10-14

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Augsburg, Berlin, Brandenburg an der Havel, Duisburg, Frankfurt am Main, Halle, Hamburg, Hanover

2024-10-10

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Cologne, Hanover, Mannheim, München

2024-10-08

Recruiting

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

NCT06607302Cholangiocarcinoma

iOMEDICO AG

Observational

100

Augsburg, Bad Liebenwerda, Bad Mergentheim, Berlin, Dresden, Essen, Hanover, Hof

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Esslingen am Neckar, Ulm, Kempten (Allgäu), München, Marburg, Hanover, Dortmund, Herne

2024-10-07

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Augsburg, Bonn, Cottbus, Hanover, Mainz

2024-09-30

Active, closed

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

NCT06603311Compensated Liver Disease (Disorder), Hepatitis D, Chronic

Hannover Medical School

Not applicable

Heidelberg, Frankfurt am Main, Hanover, Berlin

2024-09-30

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Bonn, Dortmund, Dresden, Greifswald, Hamburg, Hanover, Mannheim, München

2024-09-25

Recruiting

Prospective WCD Post CABG Registry (CABG Registry)

NCT06570902Cardiomyopathy Ischemic, Cardiomyopathies, Cardiovascular Diseases, Heart Disease, Ischemic

Zoll Medical Corporation

Observational

910

Bad Nauheim, Hanover, Cottbus, Halle

2024-09-23

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Bonn, Göttingen, Hanover, Leipzig, Ludwigshafen am Rhein, Münster, Tübingen

2024-09-19

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

Bochum, Göttingen, Hanover, Leipzig, Ulm

2024-09-17

Recruiting

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

NCT06147843Amyotrophic Lateral Sclerosis

University Hospital, Limoges

Not applicable

1,000

Hanover, Ulm

2024-09-17

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Düsseldorf, Hanover, Munich

2024-09-10

Recruiting

Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer

Universitätsklinikum Hamburg-Eppendorf

Not applicable

130

Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck

2024-08-30

Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis

DrugsKYV-101·Fludarabine·Cyclophosphamide

Kyverna Therapeutics

Phase 2/3

Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm

2024-08-28

Recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

NCT06440993Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA

DrugsDurvalumab·Gemcitabine·Cisplatin

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Aachen, Bonn, Cologne, Düsseldorf, Frankfurt, Göttingen, Hanover, Lübeck

2024-08-23

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Berlin, Bochum, Bremen, Essen, Göttingen, Hanover, Homburg, Münster

2024-08-21

Recruiting

Chronic Outcome Monitoring for DBS in Dystonia

NCT07244549Dystonia

Charite University, Berlin, Germany

Observational

Hanover, Düsseldorf, Berlin

2024-08-16

Recruiting

Development of a Novel Non-invasive Inflammometry Following Allergen Challenge in Patients With Mild Allergic Asthma

NCT06317909Mild Allergic Asthma

Fraunhofer-Institute of Toxicology and Experimental Medicine

Not applicable

Hanover

2024-08-09

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Frankfurt, Hanover, München, Münster

2024-08-07

Active, closed

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

10,212

Weinheim, Dachau, Munich, Hanover, Cologne, Essen, Goch, Freiberg

2024-08-01

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck

2024-07-19

Recruiting

German-funded Laparoscopic Approach to Cervical Cancer

NCT06489795Cervical Cancer

Hannover Medical School

Not applicable

756

Ludwigsburg, Tübingen, Bad Homburg, Göttingen, Hanover, Lüneburg, Bielefeld, Düsseldorf

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin

2024-07-16

Active, closed

Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

NCT06149650Chronic Limb-Threatening Ischemia

Cardiovascular and Interventional Radiological Society of Europe

Observational

400

Cologne, Essen, Hanover, Heilbronn, Karlsruhe, Mülheim, Neumünster, Rendsburg

2024-07-15

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel

2024-06-29

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Würzburg, Frankfurt am Main, Hanover, Aachen, Cologne, Mainz, Homburg, Berlin

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München

2024-06-25

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Freiburg im Breisgau, Ludwigsburg, Tübingen, Erlangen, Munich, Potsdam, Georgsmarienhütte, Hanover

2024-06-24

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Ulm, Augsburg, Bayreuth, Erlangen, Langen, Hanover, Koblenz, Halle

2024-06-19

Active, closed

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

NCT06391450Autosomal Dominant Polycystic Kidney

DrugDapagliflozin

Hannover Medical School

Phase 4

Hanover

2024-06-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Pforzheim, München, Ulm, Hanover, Lüneburg, Rostock, Cologne, Duisburg

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel

2024-06-03

Recruiting

Long-term Follow-up of Children Born in the PETN Studies

NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children

Jena University Hospital

Observational

228

Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle

2024-06-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Chemnitz, Frankfurt, Freiburg im Breisgau, Hanover, Homburg, Münster

2024-05-24

Recruiting

Anti-viral Action Against Type 1 Diabetes Autoimmunity

NCT06452654Diabetes Mellitus, Type 1

DrugSodium Chloride Inj

Technical University of Munich

Phase 4

2,252

Munich, Hanover, Dresden

2024-05-08

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Ahrensburg, Bamberg, Berlin, Bonn, Coswig, Essen, Hamburg, Hanover

2024-05-06

Recruiting

A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial

NCT04183660Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure

Hemovent GmbH

Observational

Hanover, Essen, Halle, Erfurt

2024-04-30

Active, closed

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

NCT07008729Chronic Heart Failure, Heart Transplant Recipient, Left Ventricular Assist Device

Puerta de Hierro University Hospital

Not applicable

390

Hanover

2024-04-24

Active, closed

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

NCT06178445Biliary Tract Cancer, HER2 Gene Mutation, HER2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Augsburg, Berlin, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg, Hanover, München

2024-04-17

Active, closed

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935Crohn's Disease

DrugsTremfya·Guselkumab

Janssen-Cilag Ltd.

Phase 3

120

Augsburg, Berlin, Dachau, Frankfurt, Göttingen, Halle, Hanover, Kiel

2024-04-17

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Munich, München, Rosenheim, Hanover, Frankfurt, Essen, Mainz, Leipzig

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Aachen, Berlin, Erlangen, Essen, Greifswald, Hanover, Mainz, München

2024-03-29

Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

NCT06163430Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

180

Aachen, Berlin, Frankfurt am Main, Hanover, Jena, Mannheim, München

2024-03-26

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Chemnitz, Frankfurt am Main, Freiburg im Breisgau, Hanover, Homburg, Münster

2024-03-13

Recruiting

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

NCT06268769Immunosuppression

DrugsTacrolimus Pill·Envarsus·Tacrolimus

Edward Geissler

Phase 4

300

Aachen, Berlin, Dresden, Hamburg, Hanover, Jena, Mainz, Münster

2024-03-09

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

Aachen, Berlin, Hanover, Tübingen

2024-03-01

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg

2024-01-11

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Baden, Frankfurt, Hamburg, Hanover, Heidelberg, München

2023-12-20

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

München, Nuremberg, Marburg, Hanover, Moers, Münster, Mainz, Großhansdorf

2023-12-15

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

220

Aachen, Augsburg, Bergisch Gladbach, Bottrop, Bremen, Cologne, Dresden, Hanover

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig

2023-12-14

Active, closed

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)

DrugGB-0895

Generate Biomedicines

Phase 1

156

Berlin, Frankfurt, Hanover

2023-12-12

Recruiting

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

NCT05714930Systemic Lupus Erythematosus

Heinrich-Heine University, Duesseldorf

Not applicable

606

Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen

2023-12-12

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

Konstanz, Munich, Hanover, Chemnitz, Frankfurt am Main, Gauting, Rosenheim

2023-12-11

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Dresden, Hanover, Oldenburg in Holstein, Ulm

2023-12-11

Active, closed

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972Ulcerative Colitis

Gilead Sciences

Phase 2

176

Berlin, Hanover, Kiel, Liepzig, Ulm

2023-12-05

Active, closed

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

257

Aschaffenburg, Berlin, Cologne, Essen, Göppingen, Hamburg, Hanover, München

2023-12-05

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Aachen, Halle, Hanover, Mannheim, Minden, Ulm

2023-12-04

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Essen, Giessen, Hanover, Potsdam, Würzburg

2023-11-29

Active, closed

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837Pulmonary Disease, Chronic Obstructive

DrugGSK3862995B

GlaxoSmithKline

Phase 1

127

Ahrensburg, Berlin, Dresden, Frankfurt, Hamburg, Hanover, Immenhausen, Leipzig

2023-11-27

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig

2023-11-23

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Aachen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hanover, Jena, Leipzig

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Würzburg, Münster, Jena, Hamburg, Hanover

2023-11-13

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Aachen, Bad Oeynhausen, Berlin, Dresden, Hanover, Mainz, München

2023-11-07

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Rosenheim, Hanover, Bad Berka, Coswig, Essen, Immenhausen, Löwenstein, München

2023-10-30

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover

2023-10-27

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Ulm, Dachau, Munich, Frankfurt am Main, Hanover, Lüneburg, Duisburg, Minden

2023-10-25

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

München, Berlin, Freiburg im Breisgau, Hanover, Heidelberg, Kiel

2023-10-20

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Bad Friedrichshall, Heidelberg, Mannheim, Nuremberg, Wallerfing, Bad Nauheim, Frankfurt am Main, Hanover

2023-10-09

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

München, Hanover, Leipzig

2023-10-05

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover

2023-10-02

Active, closed

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

NCT06095713Fabry Disease

DrugPegunigalsidase-alfa

Universität Münster

Observational

Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg

2023-10-01

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen

2023-09-21

Active, closed

Avacostar - (PASS)

NCT05897684ANCA-associated Vasculitis

Vifor Fresenius Medical Care Renal Pharma

Observational

507

Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover

2023-09-11

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Freiburg im Breisgau, Hanover, Essen, Berlin, Hamburg

2023-09-09

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Berlin, Essen, Frankfurt, Großhansdorf, Hanover, Immenhausen, Jena, Konstanz

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München

2023-09-07

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

Bad Oeynhausen, Bremen, Hanover, Stuttgart, Tübingen

2023-09-01

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

Berlin, Hamburg, Hanover, Herne

2023-08-31

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Chemnitz, Hanover

2023-08-16

By invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

174

Berlin, Essen, Hanover

2023-08-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Leipzig, Aachen, Berlin, Cologne, Hanover, Mainz, Stuttgart, Villingen-Schwenningen

2023-08-08

Active, closed

The BD Liverty™ TIPS Stent Graft Study

NCT05711316Portal Hypertension, TIPS

C. R. Bard

Not applicable

177

Berlin, Bonn, Dresden, Frankfurt, Hanover, Münster

2023-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443Moderate to Severe Asthma

DrugsIcs-Laba·Povorcitinib

Incyte Corporation

Phase 2

247

Bendorf, Bonn, Frankfurt am Main, Hanover, Mainz

2023-07-11

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

212

Halle, Hanover, Leipzig, Ulm

2023-07-07

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen

2023-07-06

Recruiting

The "Seamless" Patient:From Preoperative Preparation to Postoperative Rehabilitation

NCT06699446Heart Failure

Hannover Medical School

Not applicable

300

Hanover

2023-06-28

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938Hemophilia B

CSL Behring

Observational

500

Berlin, Bonn, Frankfurt, Hanover

2023-06-15

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Heidelberg, Dachau, Erlangen, Kassel, Hanover, Minden, Remscheid, Worms

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Aachen, Bielefeld, Essen, Freiburg im Breisgau, Georgsmarienhütte, Göttingen, Hamburg, Hanover

2023-06-07

Recruiting

PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G

NCT05810480Autoimmune Hepatitis, Autoimmune Liver Disease

Hannover Medical School

Observational

400

Aachen, Hamburg, Hanover, Heidelberg, Lübeck, Rostock

2023-06-06

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg

2023-06-05

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Freiburg im Breisgau, Heidelberg, Erlangen, Hanover, Berlin

2023-05-31

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel

2023-05-17

Active, closed

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

NCT05676203Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugDocetaxel

Jena University Hospital

Phase 3

250

Heidelberg, Wetzlar, Hanover, Planegg, Duisburg, Paderborn, Würselen, Halle

2023-05-16

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Baden-Württemberg, Bayern, Berlin, Bottrop, Erlangen, Gera, Hamburg, Hanover

2023-05-08

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Berlin, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau, Hanover, München

2023-05-03

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

Halle, Hanover

2023-05-01

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Dresden, Hamburg, Hanover, München, Nürtingen, Ulm

2023-04-21

Recruiting

The DefiPace Study

NCT04804748Post-operative Atrial Fibrillation POAF

Institut für Pharmakologie und Präventive Medizin

Observational

450

Erlangen, Nuremberg, Würzburg, Oldenburg, Dresden, Freiburg im Breisgau, Hanover, Jena

2023-03-28

Active, closed

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease

Merck Sharp & Dohme LLC

Phase 2

129

Heidelberg, Giessen, Hanover, Dresden, Lübeck

2023-03-16

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Aachen, Berlin, Hanover, Kiel, Tübingen

2023-03-06

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Freiburg im Breisgau, Augsburg, Erlangen, Würzburg, Frankfurt am Main, Hanover, Essen, Leipzig

2023-02-27

Recruiting

D-SOLVE Cohorts (Cohort A and B)

NCT06160635HDV, HDV Infection, Chronic Liver Disease

Hannover Medical School

Observational

750

Hanover

2023-02-22

Active, closed

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013Polycythemia Vera

Silence Therapeutics plc

Phase 1/2

Freiburg im Breisgau, Hanover

2023-01-26

By invitation

The Impact of a Dietary Fiber Enriched Diet on the Outcome of Patients with Liver Cirrhosis

NCT06634186Liver Cirrhosis

Hannover Medical School

Not applicable

Hanover

2023-01-23

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Heidelberg, München, Hanover

2023-01-19

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Ulm, Munich, Hanover, Dortmund, Kiel, Jena, Berlin, Cologne

2023-01-10

Active, closed

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

Dresden, Essen, Giessen, Hanover

2022-12-30

Active, closed

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642Chronic Obstructive Pulmonary Disease (COPD)

DrugAstegolimab

Hoffmann-La Roche

Phase 3

1,290

Lübeck, Berlin, Darmstadt, Frankfurt, Hamburg, Hanover, Heidelberg, Immenhausen

2022-12-29

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Altenburg, Berlin, Dresden, Hamburg, Hanover, Ludwigshafen, Markkleeberg, Paderborn

2022-12-27

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg

2022-12-13

Recruiting

HRS-AKI Treatment With TIPS in Patients With Cirrhosis

NCT05346393Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic

Jena University Hospital

Not applicable

124

Aachen, Berlin, Dresden, Essen, Freiburg im Breisgau, Halle, Hamburg, Hanover

2022-11-29

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Frankfurt am Main, Hamburg, Hanover, Heilbronn, Kiel, Langen, Leipzig, Ludwigsburg

2022-11-28

Active, closed

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

NCT05331183Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

297

Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena

2022-11-23

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Erlangen, Trier, Würzburg, Cottbus, Potsdam, Frankfurt am Main, Hanover, Greifswald

2022-11-21

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Berlin, Bonn, Dresden, Hanover, Jena, München, Rostock, Ulm

2022-11-15

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg

2022-11-08

Active, closed

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure

DrugDapagliflozin

University Medical Center Groningen

Phase 3

1,750

Berlin, Düsseldorf, Erlangen, Halle, Hamburg, Hanover, Heidelberg, Heilbronn

2022-11-08

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Berlin, Erlangen, Essen, Frankfurt, Giessen, Hanover, Jena, Mainz

2022-11-08

Active, closed

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446Myelodysplastic Syndromes

DrugTebapivat

Agios Pharmaceuticals, Inc.

Phase 2

Hanover, Düsseldorf, Leipzig

2022-11-07

By invitation

Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)

NCT07183020Multiple Sclerosis, Clinically Isolated Syndrome (CIS)

Skripuletz, Thomas Prof. Dr.

Observational

1,142

Hanover

2022-10-27

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Munich, München, Hanover, Leipzig, Amberg, Berlin, Chemnitz, Dresden

2022-10-24

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Mannheim, Tübingen, Frankfurt am Main, Hanover, Aachen, Bergisch Gladbach, Bonn, Essen

2022-10-14

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Berlin, Bochum, Halle, Hanover, Leipzig, Potsdam

2022-09-23

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

München, Traunstein, Weiden, Marburg, Hanover, Bonn, Düsseldorf, Kiel

2022-09-20

Active, closed

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

NCT05461170Hepatitis D, Chronic

DrugsTobevibart·Elebsiran

Vir Biotechnology, Inc.

Phase 2

Frankfurt, Hanover, Tübingen

2022-09-17

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Dachau, Duisburg, Hanover, Jerichow, Lüneburg

2022-09-13

Recruiting

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

NCT04098146Mandibular Reconstruction, Segmental Mandibular Defects

AO Innovation Translation Center

Observational

300

Tübingen, Aachen, Berlin, Hanover, Heidelberg, Leipzig, Munich, Ulm

2022-09-12

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Hanover, Dresden, Frankfurt am Main, Hamburg, München

2022-09-07

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Berlin, Essen, Hanover, München, Regensburg

2022-09-06

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Bayreuth, Cologne, Dresden, Düsseldorf, Erlangen, Hanover, Leipzig, Worms

2022-08-31

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Cologne, Dresden, Berlin, Hanover, Herne

2022-08-04

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

NCT04165486Multiple System Atrophy

Ionis Pharmaceuticals, Inc.

Phase 1

Ulm, Düsseldorf, Göttingen, Hanover, Marburg, München

2022-07-21

Recruiting

International Wilson's Disease Patient Registry (iWilson Registry)

NCT05239858Wilson's Disease

Orphalan

Observational

500

Berlin, Düsseldorf, Hanover, Leipzig

2022-06-29

Active, closed

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

NCT05281328Polycystic Liver Disease

DrugCAM2029

Camurus AB

Phase 2/3

Hanover, Leipzig, Münster

2022-06-28

Active, closed

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

NCT05422222Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

210

Berlin, Essen, Hanover

2022-06-21

Recruiting

Registry of Patients Having Received oNKord®

NCT05290662AML

Glycostem Therapeutics BV

Observational

Hanover

2022-06-14

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Aachen, Cologne, Dresden, Hamburg, Hanover, Lübeck, Mainz, Villingen-Schwenningen

2022-05-30

Active, closed

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT05300724Age-Related Macular Degeneration

Genentech, Inc.

Observational

400

Bonn, Freiburg im Breisgau, Göttingen, Hanover, Leipzig, Münster, Tübingen

2022-05-27

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Dresden, Duisburg, Hamburg, Hanover, München, Tübingen

2022-05-23

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Aschaffenburg, Bonn, Frankfurt am Main, Georgsmarienhütte, Hanover, Heilbronn, Koblenz Am Rhein, Langen

2022-05-16

Active, closed

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

NCT05134012Coronary Artery Disease

MedTrace Pharma A/S

Phase 3

215

Freiburg im Breisgau, Hanover

2022-05-08

Active, closed

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

NCT05174650Intrahepatic Cholangiocarcinoma

DrugsTecentriq·Atezolizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Bad Saarow, Berlin, Bonn, Cologne, Esslingen am Neckar, Frankfurt, Hanover, Krefeld

2022-04-20

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Bad Saarow, Berlin, Essen, Hamburg, Hanover, Mannheim

2022-04-14

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg

2022-03-28

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Lenvatinib·Durvalumab

AstraZeneca

Phase 3

760

Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover

2022-03-28

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Heidelberg, Immenhausen, Hanover, Großhansdorf, Gera

2022-03-24

Active, closed

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133Lupus Nephritis

DrugAnifrolumab

AstraZeneca

Phase 3

363

Cologne, Dresden, Hanover, Heidelberg, Kirchheim, Mainz Am Rhein

2022-02-15

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Erfurt, Erlangen, Essen, Esslingen am Neckar, Georgsmarienhütte, Gütersloh, Hanover, Oldenburg

2022-02-07

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Berlin, Braunschweig, Cologne, Dachau, Duisburg, Halle, Hanover, Jerichow

2022-01-19

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Heidelberg, Löwenstein, Gauting, München, Immenhausen, Georgsmarienhütte, Hanover, Münster

2021-12-20

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Giessen, Hanover, Jena, München, Rostock

2021-12-10

Active, closed

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT05177835Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 2

203

Frankfurt, Halle, Hanover

2021-12-03

Recruiting

A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

NCT04996433Persistent Depressive Disorder, Treatment-resistant Depression

University of Greifswald

Not applicable

396

Berlin, Bonn, Hanover, Jena, Lübeck, Marburg, München, Tübingen

2021-12-01

Recruiting

High Dose Steroids in Children With Stroke

NCT04873583Paediatric Stroke

DrugsSolu-Medrol·Methylprednisolone·Prednisolone

Insel Gruppe AG, University Hospital Bern

Phase 3

Freiburg im Breisgau, München, Düsseldorf, Münster, Berlin, Hanover

2021-11-16

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Hamburg, Hanover, München, Ulm

2021-10-28

Recruiting

tTF-NGR Randomized Study - STS

NCT05597917Soft Tissue Sarcoma

DrugTrabectedin

Universität Münster

Phase 3

126

Bad Saarow, Berlin, Dresden, Hanover, Heidelberg, Mainz, München, Münich

2021-10-26

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Cologne, Essen, Hanover

2021-10-22

Active, closed

Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)

NCT05082454Aortic Valve Disease

JOTEC GmbH

Observational

108

Hanover, Magdeburg

2021-10-20

Active, closed

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

DrugsMirvetuximab Soravtansine·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel

AGO Research GmbH

Phase 2

136

Berlin, Dessau, Dresden, Essen, Frankfurt, Hamburg, Hanover, Karlsruhe

2021-10-13

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Ludwigsburg, Donauwörth, Erlangen, München, Frankfurt am Main, Hanover, Essen, Mönchengladbach

2021-10-04

Recruiting

Safe and Timely Antithrombotic Removal (STAR) Registry

NCT05077124Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative

CytoSorbents, Inc

Observational

1,000

Coswig, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Kiel, Leipzig

2021-09-30

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Chemnitz, Frankfurt, Hanover, Kiel, Leipzig, Magdeburg, Münster, Tübingen

2021-09-22

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Heidelberg, Kiel

2021-09-20

Recruiting

Clinical Results and RSA Migration Analysis of the GLOBAL ICON - Stemless Anatomic Shoulder

NCT04468178Osteoarthritis of the Shoulder

Hannover Medical School

Not applicable

Hanover

2021-09-17

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Hanover

2021-09-15

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Berlin, Cologne, Hanover, München

2021-09-12

Active, closed

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

NCT05035030Alagille Syndrome

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

Berlin, Hanover, Tübingen

2021-09-03

Active, closed

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

NCT04263480Waldenstrom Macroglobulinemia

DrugsIbrutinib·Carfilzomib

Christian Buske

Phase 2

Berlin, Bremen, Dortmund, Dresden, Hamburg, Hanover, Landshut, Munich

2021-08-18

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Munich, Würzburg, Frankfurt am Main, Hanover, Cologne, Essen, Münster, Dresden

2021-08-16

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Bielefeld, Bochum, Cologne, Düsseldorf, Giessen, Hanover, Herne, Magdeburg

2021-08-05

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Greifswald, Hanover

2021-08-04

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz

2021-07-28

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Göttingen, Hanover, Cologne, Münster, Mainz

2021-07-16

Recruiting

Valved Graft PMCF Study

NCT04754217Aortic Valve Disease, Ascending Aorta Abnormality, Aortic Dissection

Abbott Medical Devices

Observational

260

Bad Oeynhausen, Berlin, Bremen, Hanover

2021-07-13

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Regensburg, Kiel, Aachen, Berlin, Frankfurt, Hamburg, Hanover, Heidelberg

2021-07-08

Active, closed

REBIRTH Active School 2.0 . a School Based Physical Activity Program

NCT04942431Primary School Children

Hannover Medical School

Not applicable

1,245

Hanover

2021-06-28

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Berlin, Dresden, Erlangen, Essen, Frankfurt, Hamburg, Hanover, Kiel

2021-06-22

Active, closed

HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

NCT04913155Lung Cancer

Hannover Medical School

Not applicable

12,100

Hanover, Großhansdorf, Lübeck

2021-05-20

Active, closed

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

DrugTofersen

Biogen

Phase 3

158

Ulm, Hanover

2021-05-17

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Heidelberg, Munich, Regensburg, Giessen, Hanover, Cologne, Dresden, Leipzig

2021-05-12

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Augsburg, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Georgsmarienhütte, Hanover

2021-05-10

Active, closed

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

NCT04863703Hepatitis D, Hepatitis B, Portal Hypertension, Liver Cirrhosis

DrugBulevirtide

Hannover Medical School

Observational

Hanover

2021-05-07

Recruiting

A Non-interventional Registry for Patients With Hepatitis B Virus Infection

NCT05051098Hepatitis B Virus Infection

Hannover Medical School

Observational

3,000

Hanover

2021-05-06

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Lenvatinib·Atezolizumab

Hoffmann-La Roche

Phase 3

557

Frankfurt, Hanover, Mainz, Tübingen, Ulm

2021-04-26

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Berlin, Düsseldorf, Giessen, Hanover, Kiel, München, Münster, Regensburg

2021-04-24

Active, closed

Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

NCT04769037Diabetes Mellitus, Type 1

Helmholtz Zentrum München

Not applicable

1,149

Dresden, Hanover, Munich

2021-04-22

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Berlin, Bochum, Bonn, Frankfurt, Hanover, Leipzig, Lübeck, Magdeburg

2021-04-01

Active, closed

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III

DrugAutogene Cevumeran

BioNTech SE

Phase 2

327

Berlin, Bochum, Bonn, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg

2021-03-08

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Heilbronn, Ludwigsburg, Tübingen, Hanover, Bonn, Essen, Dresden, Lübeck

2021-01-10

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Berlin, Cologne, Hanover, Heidelberg, Iserlohn, Leipzig, Mainz, München

2021-01-07

Active, closed

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

NCT04720326Prophylaxis Against Liver Transplant Rejection

DrugsTacrolimus Pill·Envarsus·Tacrolimus

Edward Geissler

Phase 4

268

Aachen, Berlin, Essen, Frankfurt, Hamburg, Hanover, Heidelberg, Jena

2020-12-23

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Munich, Frankfurt am Main, Hanover, Leipzig, Berlin, Charlottenburg, Dresden, Hamburg

2020-12-21

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308Primary Sclerosing Cholangitis

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

182

Hanover, Bonn, Berlin, Erlangen, Kiel, Leipzig, Magdeburg, Tübingen

2020-12-18

Active, closed

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544Hepatocellular Carcinoma Non-resectable, HCC

DrugsTremelimumab·Durvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München

2020-12-15

Active, closed

Atrasentan in Patients With IgA Nephropathy

NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy

DrugsAtrasentan·Zigakibart

Novartis Pharmaceuticals

Phase 3

404

Cloppenburg, Hanover, Hoyerswerda, Jena, Villingen-Schwenningen, Würzburg

2020-12-11

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

Augsburg, Braunschweig, Dresden, Duisburg, Düesseldorf, Essen, Frankfurt am Main, Hanover

2020-12-07

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

769

Dresden, Greifswald, Hanover, Leipzig, Münster, Tübingen, Ulm, Wiesbaden

2020-12-03

Active, closed

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

NCT03991923Heart Transplantation

XVIVO Perfusion

Not applicable

230

München, Berlin, Bad Oeynhausen, Düsseldorf, Hanover

2020-11-25

Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis

Alnylam Pharmaceuticals

Observational

1,500

Berlin, Giessen, Hanover

2020-11-23

Active, closed

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)

DrugsLY3410738·Azacitidine·Venetoclax

Eli Lilly and Company

Phase 1

260

Hanover

2020-11-19

Active, closed

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

NCT04658199Progressive Supranuclear Palsy

UCB Biopharma SRL

Phase 1

Bochum, Düsseldorf, Essen, Hanover

2020-11-16

Active, closed

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

NCT04598893Diabetes Mellitus, Type 1

DrugTeplizumab

Provention Bio, a Sanofi Company

Observational

188

Bethel, Augsburg, Dresden, Hanover, Heidelberg

2020-10-26

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Nürtingen, Duisburg, Gütersloh, Münster, Lübeck, Berlin, Hamburg, Hanover

2020-10-19

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Berlin, Chemnitz, Dresden, Essen, Georgsmarienhütte, Göttingen, Hamburg, Hanover

2020-10-09

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Ulm, Würzburg

2020-10-02

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Regensburg, Frankfurt am Main, Hanover, Lüneburg

2020-09-30

Active, closed

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665Primary Biliary Cirrhosis

DrugElafibranor

Ipsen

Phase 3

161

Berlin, Frankfurt, Hanover, Kiel, Leipzig, Mainz

2020-09-24

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

Braunschweig, Cologne, Dresden, Duisburg, Hanover, München, Münster, Nürtingen

2020-09-23

Active, closed

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

NCT04503278Solid Tumor

BioNTech Cell & Gene Therapies GmbH

Phase 1

214

Berlin, Cologne, Erlangen, Hamburg, Hanover, Heidelberg, Mainz, Regensburg

2020-09-16

Active, closed

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192Non-Small Cell Lung Cancer

Razor Genomics

Not applicable

420

Cologne, Gauting, Georgsmarienhütte, Großhansdorf, Hanover, Lübeck, München, Oldenburg

2020-09-11

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Mannheim, Mutlangen, Munich, Hanover, Cologne, Düsseldorf, Leipzig, Berlin

2020-09-10

Active, closed

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

NCT04184895Allergic to House Dust Mites

Astellas Pharma Global Development, Inc.

Phase 1

Berlin, Hanover

2020-09-09

Active, closed

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492Central Retinal Vein Occlusion With Macular Edema

DrugsLucentis·Ranibizumab

University of Giessen

Phase 3

Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster

2020-08-25

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Berlin, Dresden, Freiburg im Breisgau, Hanover, München, Münster, Velbert

2020-07-24

Active, closed

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304Hypereosinophilic Syndrome

DrugBenralizumab

AstraZeneca

Phase 3

134

Hanover, Kirchheim, Mannheim

2020-07-20

Active, closed

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934Hemophilia A

Baxalta now part of Shire

Observational

207

Heidelberg, Berlin, Bonn, Hanover

2020-07-09

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bad Oeynhausen, Hanover, München, Regensburg

2020-06-30

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04219254Solid Tumor, Adult

DrugKeytruda

BioInvent International AB

Phase 1/2

197

Hanover, Heidelberg, Homburg

2020-06-29

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Pforzheim, Würzburg, Frankfurt am Main, Lauterbach, Hanover, Bottrop, Wipperfürth, Leipzig

2020-06-22

Recruiting

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

NCT03838042CNS Tumor, Solid Tumor

DrugOpdivo

University Hospital Heidelberg

Phase 1/2

Augsburg, Berlin, Essen, Hanover, Heidelberg

2020-05-26

Recruiting

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

NCT03993262Autoimmune Encephalitis

DrugBortezomib

Jena University Hospital

Phase 2

München, Würzburg, Jena, Hanover, Berlin, Bochum, Düsseldorf, Erlangen

2020-05-13

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Dresden, Erlangen, Essen, Frankfurt, Gelsenkirchen, Hamburg, Hanover, Heidelberg

2020-04-16

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

München, Würzburg, Hanover, Essen, Mainz, Magdeburg, Berlin, Hamburg

2020-02-11

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03969329Secondary Hyperparathyroidism

DrugEtelcalcetide

Amgen

Phase 3

Bonn, Cologne, Hamburg, Hanover, Heidelberg

2019-12-20

Active, closed

Cold Agglutinin Disease Real World Evidence Registry

NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)

RECORDATI GROUP

Observational

429

Essen, Hanover, Landshut

2019-12-12

Recruiting

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

NCT04202341Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Observational

500

Hanover

2019-12-02

Active, closed

NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

Universitätsklinikum Hamburg-Eppendorf

Phase 2

167

Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Leipzig, Münster

2019-11-14

Active, closed

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

NCT04238637Intrahepatic Cholangiocarcinoma

DrugsTremelimumab·Durvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Dresden, Essen, Halle, Hanover, Jena, Munich

2019-11-01

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

München, Bonn, Buxtehude, Dresden, Essen, Gera, Göttingen, Hanover

2019-10-28

Active, closed

SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy

NCT03924661Aortic Valve Disease

Abbott Medical Devices

Observational

Stuttgart, München, Leipzig, Hanover

2019-10-24

Recruiting

Alloplastic Total Temporomandibular Joint (TMJ) Replacement Registry

NCT03991728Temporomandibular Joint Disorders

AO Innovation Translation Center

Observational

200

Hanover, Leipzig, Mainz, Munich

2019-10-15

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Berlin, Halle, Hanover, Jerichow, Lüneburg, Saarbrücken, Ulm

2019-09-26

Active, closed

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia

DrugsZiftomenib·Itraconazole·Midazolam

Kura Oncology, Inc.

Phase 1/2

263

Greifswald, Hanover

2019-09-12

Recruiting

TIPS in Patients With Decompensated Liver Cirrhosis

NCT04801290Decompensated Liver Cirrhosis

Hannover Medical School

Observational

250

Hanover

2019-08-29

Recruiting

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

NCT04832607AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications

Tobias Feuchtinger

Phase 3

149

Berlin, Dresden, Düsseldorf, Essen, Freiburg im Breisgau, Hanover, Leipzig, Munich

2019-08-27

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

665

Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz

2019-08-12

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Dresden, Essen, Hamburg, Hanover, Heidelberg, Marburg, Munich

2019-08-05

Active, closed

SIRONA 2 Trial Heart Failure NYHA Class III

NCT04012944Heart Failure NYHA Class III

Endotronix, Inc.

Not applicable

Cologne, Giessen, Hanover

2019-06-26

Active, closed

Automatic PredICtion of Edema After Stroke

NCT04057690Stroke, Acute, Brain Edema

University Hospital Tuebingen

Observational

1,687

Berlin, Bonn, Bremen, Düsseldorf, Hamburg, Hanover, Heidelberg, Leipzig

2019-04-01

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Dresden, Göttingen, Halle, Hanover, Heidelberg, Homburg, Regensburg, Trier

2019-03-06

Active, closed

NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

NCT03613246Transcatheter Aortic Valve Implantation

NVT GmbH

Observational

346

Bad Bevensen, Bad Rothenfelde, Hamburg, Hanover, Heilbronn

2019-02-20

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

Friedrichshafen, Erlangen, Munich, Offenbach, Wiesbaden, Hanover, Bonn, Essen

2018-12-27

Active, closed

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850Immunoglobulin A Nephropathy

DrugsSparsentan·Irbesartan·Dapagliflozin

Travere Therapeutics, Inc.

Phase 3

406

Villingen-Schwenningen, Hanover, Aachen, Düsseldorf, Kaiserslautern, Trier, Kiel, Jena

2018-12-11

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Ravensburg, Munich, Würzburg, Cottbus, Frankfurt am Main, Georgsmarienhütte, Hanover, Essen

2018-12-07

Active, closed

CoreHip - Post Market Clinical Follow-Up Study

NCT03685110Degenerative Osteoarthritis, Rheumatic Arthritis, Fractures, Hip, Necrosis, Femur Head

Aesculap AG

Observational

248

Markgröningen, München, Hanover, Salzkotten

2018-10-16

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

DrugCabozantinib

Exelixis

Phase 3

187

Tübingen, Würzburg, Marburg, Hanover, Dresden, Magdeburg, Aachen, Bonn

2018-10-05

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Mannheim, Tübingen, Munich, Nuremberg, Würzburg, Buxtehude, Hanover, Essen

2018-09-12

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Tübingen, Erlangen, Munich, Frankfurt am Main, Buxtehude, Hanover, Essen, Homburg

2018-08-21

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Heidelberg, Frankfurt am Main, Münster, Selters, Kiel, Bonn, Hamburg, Hanover

2018-08-09

Active, closed

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945Ulcerative Colitis

DrugMirikizumab

Eli Lilly and Company

Phase 3

1,058

Berlin, Brandenburg, Halle, Hamburg, Hanover, Ludwigshafen

2018-07-18

Active, closed

Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography

NCT03377036Breast Cancer Screening

University Hospital Muenster

Not applicable

99,689

Hanover, Lüneburg, Stade, Vechta, Wilhelmshaven, Aachen, Ahlen, Bergisch Gladbach

2018-07-05

Recruiting

Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators

NCT04732910Cystic Fibrosis

Charite University, Berlin, Germany

Observational

500

Berlin, Giessen, Hanover, Heidelberg

2018-07-01

Recruiting

Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)

NCT03469609Enterostomy

University of Leipzig

Not applicable

120

Tübingen, München, Frankfurt am Main, Hanover, Witten, Mainz, Dresden, Leipzig

2018-06-18

Active, closed

Thoraflex Hybrid Post-Market Study

NCT03414866Acute Aortic Dissection, Aortic Rupture, Penetrating Aortic Ulcer, Aortic Dissection

Vascutek Ltd.

Observational

182

Freiburg im Breisgau, Hanover

2018-05-25

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Berlin, Cologne, Duisburg, Hanover, Heidelberg, Marburg, Mettmann, Mühlheim An Der Ruhr

2018-05-14

Active, closed

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

NCT03386734Cervical Cancer

Centre Hospitalier Universitaire de Besancon

Not applicable

989

Berlin, Dresden, Düsseldorf, Essen, Fürth, Giessen, Hamburg, Hanover

2018-05-03

By invitation

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)

Prof. Valérie Mc Lin

Observational

500

Hanover, Munich, Tübingen

2018-04-26

Active, closed

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458Hepatocellular Carcinoma, Liver Cancer

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

545

Aachen, Berlin, Bonn, Cologne, Essen, Frankfurt am Main, Hanover, Homburg

2018-04-18

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Augsburg, Berlin, Dresden, Frankfurt, Frankfurt am Main, Hamburg, Hanover, Heidelberg

2018-04-13

Active, closed

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922Melanoma

DrugsRelatlimab·Nivolumab

Bristol-Myers Squibb

Phase 2/3

714

Heidelberg, Tübingen, Quedlinburg, Buxtehude, Cologne, Erfurt, Essen, Hanover

2018-04-11

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Dresden, Frankfurt am Main, Hamburg, Hanover, Leipzig, München, Witten

2018-03-07

Recruiting

Registry for Patients With Lipodystrophy

NCT03553420Lipodystrophy Acquired, Lipodystrophy Congenital

University of Ulm

Observational

5,000

Hanover, Leipzig, Münster, Ulm

2017-12-16

Recruiting

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

NCT03320304Treatment Resistant Depression

LivaNova

Observational

500

Bamberg, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Göttingen, Hanover

2017-12-14

Active, closed

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049HIV Infections

DrugsRilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

1,049

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2017-10-27

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München

2017-10-11

Recruiting

Registry for Patients With X-Linked Hypophosphatemia

NCT03193476X-Linked Hypophosphatemia

Kyowa Kirin Pharmaceutical Development Ltd

Observational

1,489

Bad Belzig, Bochum, Cologne, Dortmund, Freiburg im Breisgau, Hanover, Leipzig, Mainz

2017-09-12

Recruiting

Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases

NCT04706234Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease

Kliniken Beelitz GmbH

Observational

350

Ulm, Beelitz-Heilstätten, Hanover, Münster, Dresden, Stadtroda, Hamburg

2017-09-01

Active, closed

Kinematic Versus Mechanical Alignment in Total Knee Replacement

NCT04384913Total Knee Replacement

Hannover Medical School

Observational

130

Hanover

2017-08-01

Active, closed

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973Advanced Solid Tumors Which Are cMET-dependent

DrugsNazartinib·Capmatinib·Gefitinib·Osimertinib

Novartis Pharmaceuticals

Phase 2

Cologne, Hanover

2017-07-04

Active, closed

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

146

Essen, Chemnitz, Berlin, Hanover, Leipzig, München, Ulm

2017-06-26

Active, closed

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer

DrugsPerjeta·Herceptin·Exemestane·Anastrozole

Alliance Foundation Trials, LLC.

Phase 3

518

Bottrop, Cologne, Essen, Frankfurt, Hanover, Kiel, Münster, Schweinfurt

2017-06-21

Active, closed

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098Urothelial Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

1,314

Dresden, Essen, Freiburg im Breisgau, Hamburg, Hanover, Jena, Mannheim, Nuremberg

2017-03-24

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover

2017-02-02

Active, closed

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT02954094Hepatocellular Cancer

Target PharmaSolutions, Inc.

Observational

10,000

Aachen, Berlin, Düsseldorf, Frankfurt, Hanover, Leipzig, Magdeburg, Mainz

2016-12

Active, closed

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052Infection, Human Immunodeficiency Virus, HIV Infections

Drugs2 NRTIs·Cabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine

ViiV Healthcare

Phase 3

618

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2016-10-28

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520HIV Infections

DrugsCabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

631

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2016-10-27

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Stuttgart, Tübingen, München, Frankfurt am Main, Hanover, Greifswald, Münster, Homburg/Saar

2016-10-13

Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674Generalised Lipodystrophy, Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Observational

100

Ulm, Hanover, Münster, Leipzig

2016-10-11

Active, closed

Neoadjuvant L19IL2/L19TNF- Pivotal Study

NCT02938299Malignant Melanoma

DrugsL19IL2·Onfekafusp alfa

Philogen S.p.A.

Phase 3

214

Dresden, Hanover, Heidelberg, Kiel, Leipzig, Berlin, Tübingen, Augsburg

2016-07-01

Active, closed

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

DrugsRamucirumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 2

309

Tübingen, Ulm, Erlangen, Hanover, Berlin, Hamburg

2016-05-19

Recruiting

Vercise™ DBS Dystonia Prospective Study

NCT02686125Dystonia

Boston Scientific Corporation

Observational

300

Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Hanover, Kiel

2016-03-07

Recruiting

TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis

NCT03057860Moderate-to-severe Atopic Dermatitis

Technische Universität Dresden

Observational

2,800

Hanover, Dresden, Kiel

2016-02-01

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Bonn, Braunschweig, Eisleben Lutherstadt, Hamburg, Hanover, Leipzig, Lübeck, Nürtingen

2015-11-27

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster

2015-11-02

Recruiting

The German ADPKD Tolvaptan Treatment Registry

NCT02497521ADPKD (Autosomal Dominant Polycystic Kidney Disease)

University of Cologne

Observational

2,000

Müllheim, Würzburg, Hanover, Cologne, Nettetal, Leipzig, Lübeck, Berlin

2015-11

Recruiting

Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.

NCT05852418Amyotrophic Lateral Sclerosis

Ambulanzpartner Soziotechnologie APST GmbH

Observational

25,000

Berlin, Bochum, Bonn, Dresden, Essen, Göttingen, Hanover, Heidelberg

2015-10-30

Active, closed

Micra Transcatheter Pacing System Post-Approval Registry

NCT02536118Bradycardia

Medtronic

Observational

3,100

Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt, Hamburg, Hanover

2015-07

Active, closed

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597Urothelial Cancer

DrugsErdafitinib·Midazolam·Metformin

Janssen Research & Development, LLC

Phase 2

239

Berlin, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Greifswald, Hamburg, Hanover

2015-04-22

Recruiting

C-Brace Prospective Registry

NCT04640584Pareses, Lower Extremity

Otto Bock Healthcare Products GmbH

Observational

250

Traunstein, Göttingen, Hanover, Koblenz

2015-04

Active, closed

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251Diffuse Large B-cell Lymphoma

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

244

Aachen, Bad Saarow, Berlin, Bremen, Cologne, Dresden, Halle, Hanover

2014-11

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631Non Small Cell Lung Cancer

DrugsErlotinib·Abemaciclib

Eli Lilly and Company

Phase 3

453

Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg

2014-10-03

Active, closed

PERIGON Pivotal Trial

NCT02088554Aortic Stenosis

Medtronic Cardiac Surgery

Not applicable

1,312

Cologne, Munich, Frankfurt, Hanover, Leipzig

2014-05-12

Active, closed

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943Transfusion-dependent Beta-Thalassemia

Genetix Biotherapeutics Inc.

Observational

Hanover, Heidelberg

2014-01

Recruiting

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

NCT02852928Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis

Matthias Griese

Observational

1,000

Hanover

2013-12

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

DrugOlaparib

AstraZeneca

Phase 3

327

Berlin, Erlangen, Essen, Frankfurt, Hanover, Lübeck, München, Ravensburg

2013-09-03

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183Atypical Hemolytic-Uremic Syndrome

Alexion Pharmaceuticals, Inc.

Observational

3,000

Essen, Hanover, Heidelberg, Lübeck, Münster, Tübingen

2013-03-18

Recruiting

Pediatric Arm of DZL All Age Asthma Cohort

NCT02496468Asthma, Wheeze, Hypersensitivity, Endophenotype

LMU Klinikum

Observational

1,500

Cologne, Hanover, Lübeck, Marburg, Munich

2013-01

Active, closed

Longterm-Evaluation of Vitelene® Against Standard

NCT01713062Osteoarthritis, Hip, Arthritis

Aesculap AG

Observational

400

Bendorf, Bochum, Halle, Hanover, Mülheim, Olsberg

2012-01

Recruiting

Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

NCT02270476Cystic Fibrosis Lung Disease

Heidelberg University

Observational

200

Heidelberg, Giessen, Hanover, Lübeck

2011-12

Active, closed

Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension

NCT01471834High Blood Pressure

CVRx, Inc.

Not applicable

Cologn, Düsseldorf, Göttingen, Hanover, Leipzig

2011-06

Recruiting

Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation

NCT01299168Validation Study of Molecular Diagnostic System, Development of Reporting System for Molecular Diagnosis, Incorporate Molecular Diagnosis Into Diagnostic Standards

University of Alberta

Observational

500

Berlin, Hanover

2011-05

Recruiting

Better Control in Pediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference (SWEET- Registry)

NCT04427189Type 1 Diabetes

Kinderkrankenhaus auf der Bult

Observational

100,000

Hanover

2008-04

Active, closed

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990Brain and Central Nervous System Tumors

DrugsTemodal·Temodar·Temozolomide

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

751

Bamberg, Bonn, Hanover, Heidelberg, Regensburg, Tübingen

2007-12

Recruiting

COMPERA / COMPERA-KIDS

NCT01347216Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)

Technische Universität Dresden

Observational

14,000

Berlin, Giessen, Hanover, Munich

2007-07-01

Recruiting

Epidemiological Study on Community Acquired Pneumonia

NCT02139163Community Acquired Pneumonia

Capnetz Stiftung

Observational

20,000

Hanover

2002-10

By invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

NCT02699736HIV, Hepatitis B, Hepatitis C, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

23,000

Bonn, Cologne, Eppendorf, Frankfurt am Main, Hamburg, Hanover, München

1994-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 October 2026. https://priyalifescience.com/clinical-trials-germany/city/hanover

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,060 studies in total at the last sync on 14 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 486 of those studies with a site in Hanover.

How many clinical trials are recruiting in Hanover?

237 of the 486 studies on this page are recruiting new participants as of the 14 Oct 2026, 03:18 UTC sync. A further 12 have not yet opened recruitment, 230 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hanover), 486 studies
Phase	Studies	Recruiting	Share
Phase 3	222	92	45.7%
Observational	87	55	17.9%
Phase 2	74	31	15.2%
Not applicable	50	28	10.3%
Phase 2/3	16	10	3.3%
Phase 1	14	6	2.9%
Phase 1/2	14	10	2.9%
Phase 4	9	5	1.9%

Most active sponsors

Lead sponsors with the most studies (Hanover)
Lead sponsor	Studies	Recruiting
AstraZeneca	42	17
Hannover Medical School	25	16
Janssen Research & Development, LLC	17	9
Eli Lilly and Company	16	7
Merck Sharp & Dohme LLC	16	6
Hoffmann-La Roche	15	6
Novartis Pharmaceuticals	15	7
Bristol-Myers Squibb	11	4
Boehringer Ingelheim	10	6
AbbVie	9	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.